Molecular Biology Research Technique – Page 3

Revolutionizing AATD Treatment: Emerging Therapies to Replace Augmentation Therapy

7 months ago talkbio0Tagged alpha 1-Antitrypsin Deficiency, Alpha-1, Antitrypsin Deficiency, augmentation therapy, Clustered Regularly Interspaced Short Palindromic Repeats, Gene Modification, Hereditary Diseases, RNA Interference

Alpha-1 Antitrypsin Deficiency (AATD), Genetic Disorder, New Therapies, Augmentation Therapy, RNA Interference (RNAi), Gene Editing, CRISPR

Intellia’s CRISPR Therapy NTLA-2002 Shows 81% Reduction in Hereditary Angioedema Attacks in Phase 2 Study

8 months ago talkbio0Tagged Angioedemas, Hereditary, Clustered Regularly Interspaced Short Palindromic Repeats, Functional, Gene Modification, Intellia, NTLA-2002, Phase 2 Clinical Trials, Swelling attacks

CRISPR therapy, Intellia Therapeutics, NTLA-2002, Hereditary Angioedema (HAE), Gene editing, Phase 2 study, Swelling attacks, Functional cure

Intellia’s CRISPR Gene Editing Therapy Shows Promising Results in Reducing HAE Attacks

8 months ago talkbio0Tagged Angioedemas, Hereditary, Clinical Trials, Clustered Regularly Interspaced Short Palindromic Repeats, Gene Modification, gene therapy, Infrequent, Intellia

Intellia Therapeutics, CRISPR Gene Editing, Hereditary Angioedema (HAE), NTLA-2002, Clinical Trials, Gene Therapy, Rare Diseases

Illumina Introduces MiSeq i100 Series: Simplifying Next-Generation Sequencing with Push-Button Workflows

8 months ago talkbio0Tagged Benchtop DNA Sequencer, DNA Sequence, Genomics, High-Throughput Nucleotide Sequencing, Illumina, MiSeq, Push-Button, Workflow

Illumina, MiSeq i100 Series, Benchtop DNA Sequencer, Push-Button Workflows, Next-Generation Sequencing (NGS), Genomics, DNA Sequencing

RNAi Revolution: Former Alnylam Team Launches $135M siRNA Engineering Startup

8 months ago talkbio0Tagged Alnylam, Cities, Genetic Engineering, RNA Interference, RNA, Small Interfering

RNAi, siRNA, Alnylam, City Therapeutics, John Maraganore, genetic engineering, biotech startup

Optimizing Expression of Multi-chain and Bispecific Antibodies: Strategies and Considerations

8 months ago talkbio0Tagged Antibodies, Antibodies, Bispecific, Cells, Chinese Hamster Ovary, CHO, Cultured Cell Line, expression vector, Metabolic Engineering, Optimization, production, Recombinants, Stable status

Bispecific Antibodies (bsAbs), Recombinant Antibody Production, Chinese Hamster Ovary (CHO) Cells, Expression Vector Optimization, Metabolic Engineering, Stable Cell Line Development

Prime Medicine Partners with Bristol Myers Squibb in $3.5B Cell Therapy Deal, Narrows Pipeline Focus

8 months ago talkbio0Tagged BMS, Burning Mouth Syndrome, Cell Therapy, Edit, ex vivo, Gene Modification, Ifosfamide/Methotrexate/Procarbazine protocol, PASSIGE, pipeline, Prime Medicine, Reprioritization, squibb, strategic collaboration, Technology

Prime Medicine, Bristol Myers Squibb (BMS), Cell Therapy, Gene Editing, Prime Editing, PASSIGE Technology, Ex Vivo T-Cell Therapies, Pipeline Reprioritization, Strategic Collaboration

FDA Approves Illumina’s TruSight Oncology Comprehensive Test for Pan-Cancer Companion Diagnostics

9 months ago talkbio0Tagged Approved, cellular targeting, Comprehensive, Diagnostics, Gene Fusion, Illumina, Neoplasms, NTRK, pan-cancer, Pet Animal, Precision - temporal, RET protein, human, TruSight Oncology, United States Food and Drug Administration

FDA approval, Illumina, TruSight Oncology Comprehensive, pan-cancer, companion diagnostics, NTRK gene fusions, RET fusion-positive NSCLC, targeted therapies, precision oncology.